##{"id":98247,"date":"2021-11-26T20:34:00","date_gmt":"2021-11-26T09:34:00","guid":{"rendered":"https:\/\/www.fnarena.com\/index.php\/2021\/11\/26\/australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel\/"},"modified":"2021-11-26T20:34:00","modified_gmt":"2021-11-26T09:34:00","slug":"australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel","status":"publish","type":"post","link":"https:\/\/staging.fnarena.com\/index.php\/2021\/11\/26\/australian-biotech-company-starpharma-announces-positive-interim-results-from-the-prostate-cancer-cohort-in-its-ongoing-phase-2-trial-of-dep-cabazitaxel\/","title":{"rendered":"Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP\u00ae cabazitaxel"},"content":{"rendered":"

MELBOURNE, Australia<\/span>, Nov. 26, 2021<\/span> \/PRNewswire\/ — Starpharma showed that 100% of evaluable patients with Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease.<\/p>\n

DEP^{®<\/sup> cabazitaxel<\/a> is a patented, detergent (polysorbate-80^{[1]<\/sup>)-free, nanoparticle version of the conventional cancer drug, Jevtana^{®<\/sup> – a leading oncology agent used to treat advanced prostate cancer. Sales of Jevtana^{®<\/sup> exceeded US$600 million<\/span> in 2020. <\/p>\n}}}}

Starpharma<\/a>‘s interim results in Stage IV prostate cancer show that one or more efficacy signals^{[2]<\/sup> were observed in 100% of patients assessed following DEP^{®<\/sup> cabazitaxel treatment.<\/p>\n}}

64% of patients with assessable tumours saw prolonged stable disease and significant reductions in tumour size for up to 36 weeks <\/li>\n

90% of patients with assessable PSA (Prostate Specific Antigen) tumour biomarker levels had a PSA reduction; >50% of these patients achieved a PSA reduction of at least 50% <\/li>\n

83% of patients with secondary bone disease exhibited either no progression or an improvement in bone disease <\/li>\n

56% of evaluable patients had responses to all three measures evaluated<\/li>\n<\/ul>\n

Starpharma’s positive interim results<\/a> are particularly significant given all patients in this cohort had late-stage prostate cancer and had failed multiple anti-cancer treatments, in addition to surgeries and radiation, prior to entering the DEP^{®<\/sup> cabazitaxel trial.<\/p>\n}

Importantly, patients treated with DEP^{®<\/sup> cabazitaxel also experienced less severe bone marrow toxicity, significantly lower rates of severe neutropenia and no instances of neutropenic sepsis, which are associated with conventional cabazitaxel. The absence of detergent-like polysorbate-80 in the DEP^{®<\/sup> cabazitaxel formulation eliminated the need for prophylactic corticosteroids and antihistamines, with no anaphylaxis or severe hypersensitivity reactions observed. This avoidance of long-term steroid use is attractive, particularly in prostate cancer patients where bone health can be a significant issue. <\/p>\n}}

DEP^{®<\/sup> cabazitaxel is one of Starpharma’s three internal clinical-stage DEP^{®<\/sup> assets, alongside DEP^{® <\/sup>docetaxel and DEP^{® <\/sup>irinotecan, which Starpharma intends to licence following phase 2. Starpharma also has a number of partnered DEP^{®<\/sup> programs including with AstraZeneca and Merck & Co., Inc.<\/p>\n}}}}}

[1] Polysorbate 80 is a detergent-like substance, which is used to solubilise insoluble molecules, and which is a component of conventional cabazitaxel products, including Jevtana^{®<\/sup> and generic forms. <\/span><\/p>\n<\/td>\n<\/tr>\n}

\n

[2] Efficacy in the prostate cancer cohort in the trial was assessed referencing the applicable aspects of the internationally recognised Prostate Cancer Working Group (PCWG3) guidelines.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

MELBOURNE, Australia, Nov. 26, 2021 \/PRNewswire\/ — Starpharma showed that 100% of evaluable patients with Stage IV prostate cancer have had…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[105],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/98247"}],"collection":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/comments?post=98247"}],"version-history":[{"count":0,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/98247\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/media?parent=98247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/categories?post=98247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/tags?post=98247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}